Press Releases September 1, 2026 08:00 AM

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

Akebia Therapeutics to Present at 2026 Wells Fargo Healthcare Conference

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
AKBA

Akebia Therapeutics announced that its CEO and CFO will participate in one-on-one meetings at the Wells Fargo Healthcare Conference in Boston, where they will discuss the company's commercial products and clinical-stage kidney disease pipeline.

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
AKBA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Akebia Therapeutics focuses on treatments for kidney disease with both commercial products and clinical programs.
  • Senior management will engage with investors at a major healthcare conference, potentially enhancing investor relations.
  • The company underscores its commitment to addressing unmet needs in the kidney disease therapeutic market.

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, which will take place in Boston, September 8 – 10, 2026.

During meetings, management will discuss its commercial products and its robust pipeline of clinical stage kidney disease programs.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
[email protected]  


Risks

  • Uncertainties remain regarding the outcomes and progress of clinical-stage kidney disease programs, which could impact future growth.
  • Market and investor response to the presentations may vary depending on the disclosed data and updates.
  • The competitive and regulatory environment within the biopharmaceutical sector may affect Akebia's commercialization efforts.

More from Press Releases

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026 Twin Disc Announces First Quarter Results Nov 4, 2026 UniFirst Declares Increased Cash Dividends Oct 30, 2026